India's High Court Delays Pfizer Sutent Decision Until Cipla Patent Ruling
This article was originally published in PharmAsia News
India's highest court has put off until early January a hearing on Pfizer's suit to block a Cipla challenge of its patent on Sutent (sunitinib) for treating gastrointestinal and other tumors.
You may also be interested in...
FDA warns OHM Pharma for promoting topical formula containing homeopathic ingredients as teething product for infants. The firm also warned about drug and supplements GMP violations and was an easy target for FDA following release of draft guidance outlining its enforcement priorities.
Richard Pazdur, FDA's oncology chief, reiterates the breakthrough therapy designation is for agency-sponsor communication and not an investor tool.